

NA Uterine Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 320 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

North America uterine cancer diagnostics market is projected to register a CAGR of 11.2% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

North America Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based and Procedure Based), Type (Endometrial Cancer and Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centres, Cancer Research Centre, Ambulatory Surgical Centres, Specialized Clinics, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the Global uterine cancer diagnostics market are:

- Increasing uterine cancer patients among the women population
- Rise in technological advancement for uterine cancer diagnostic

Market Players

The key market players operating in the North America uterine cancer diagnostics market are:

- F-Hoffmann La Roche Ltd.
- Siemens Healthcare Private Limited
- ESAOTE SPA
- Narang Medical Limited
- Olympus Corporation
- Integra LifeSciences
- KARL STORZ SE & Co. KG
- Stryker
- General Electric Company
- FUJIFILM Corporation

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Koninklijke Philips N.V.
- B. Braun SE
- AED.MD
- GRAIL

Table of Contents:

TABLE OF CONTENTS	
1 INTRODUCTION	117
1.1 OBJECTIVES OF THE STUDY	117
1.2 MARKET DEFINITION	117
1.3 OVERVIEW OF THE NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET	117
1.4 CURRENCY AND PRICING	119
1.5 LIMITATIONS	119
1.6 MARKETS COVERED	119
2 MARKET SEGMENTATION	127
2.1 MARKETS COVERED	127
2.2 GEOGRAPHICAL SCOPE	128
2.3 YEARS CONSIDERED FOR THE STUDY	129
2.4 DBMR TRIPOD DATA VALIDATION MODEL	130
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	133
2.6 MULTIVARIATE MODELLING	134
2.7 MARKET APPLICATION COVERAGE GRID	135
2.8 INSTRUMENT BASED LIFELINE CURVE	136
2.9 DBMR MARKET POSITION GRID	137
2.10 VENDOR SHARE ANALYSIS	139
2.11 SECONDARY SOURCES	140
2.12 ASSUMPTIONS	140
3 EXECUTIVE SUMMARY	141
4 PREMIUM INSIGHTS	144
4.1 PESTEL ANALYSIS	145
4.2 PORTER'S FIVE FORCES	146
4.3 PATENT ANALYSIS OF NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET	147
4.4 REIMBURSEMENT SCENARIO	148
4.5 INDUSTRY INSIGHTS:	149
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES	149
4.7 PRICING STRATEGIES	149
4.8 CONCLUSION	150
4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER	151
4.10 COST OF UTERINE CANCER PROCEDURE	153
5 REGULATORY FRAMEWORK	154
6 MARKET OVERVIEW	156
6.1 DRIVERS	158
6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS	158
6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES	158
6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER	159

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH	159
6.2 RESTRAINTS	160
6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS	160
6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER	160
6.3 OPPORTUNITIES	161
6.3.1 INCREASING PREVALENCE OF UTERINE CANCER	161
6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE	161
6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS	162
6.4 CHALLENGES	162
6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE	162
6.4.2 HIGH COST OF IMAGING SYSTEMS	163
7 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE	164
7.1 OVERVIEW	165
7.2 INSTRUMENT-BASED	168
7.2.1 ULTRASOUND SCANNING	169
7.2.1.1 SYSTEMS	169
7.2.1.2 ABDOMINAL ULTRASOUND SCANNING	170
7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING	170
7.2.1.4 ACCESSORIES	170
7.2.2 IMAGING DEVICES	170
7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN	171
7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI)	171
7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN	171
7.2.2.4 OTHERS	171
7.2.3 TESTS	172
7.2.3.1 BLOOD TESTS	172
7.2.3.1.1 COMPLETE BLOOD COUNT	172
7.2.3.1.2 CA125 MARKER BLOOD TEST	172
7.2.3.2 URINE TESTS	173
7.2.3.3 OTHER TESTS	173
7.2.4 OTHERS	173
7.3 PROCEDURE BASED	173
7.3.1 ENDOMETRIAL BIOPSY	174
7.3.2 HYSTEROSCOPY	174
7.3.3 DILATION & CURETTAGE	174
7.3.4 CYSTOSCOPY	174
7.3.5 PROCTOSCOPY	175
7.3.6 OTHERS	175
8 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE	176
8.1 OVERVIEW	177
8.2 ENDOMETRIAL CANCER	180
8.2.1 SEROUS ADENOCARCINOMA	181
8.2.1.1 INSTRUMENT-BASED	181
8.2.1.1.1 ULTRASOUND SCANNING	182
8.2.1.1.2 IMAGING DEVICES	182
8.2.1.1.3 TESTS	182
8.2.1.1.4 OTHERS	182

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.2.1.2	PROCEDURE-BASED	183
8.2.1.2.1	ENDOMETRIAL BIOPSY	183
8.2.1.2.2	HYSTEROSCOPY	183
8.2.1.2.3	DILATION & CURETTAGE	183
8.2.1.2.4	CYSTOSCOPY	183
8.2.1.2.5	PROCTOSCOPY	183
8.2.1.2.6	OTHERS	184
8.2.2	ADENOSQUAMOUS CARCINOMA	184
8.2.2.1	INSTRUMENT-BASED	184
8.2.2.1.1	ULTRASOUND SCANNING	184
8.2.2.1.2	IMAGING DEVICES	185
8.2.2.1.3	TESTS	185
8.2.2.1.4	OTHERS	185
8.2.2.2	PROCEDURE-BASED	185
8.2.2.2.1	ENDOMETRIAL BIOPSY	185
8.2.2.2.2	HYSTEROSCOPY	185
8.2.2.2.3	DILATION & CURETTAGE	186
8.2.2.2.4	CYSTOSCOPY	186
8.2.2.2.5	PROCTOSCOPY	186
8.2.2.2.6	OTHERS	186
8.2.3	UTERINE CARCINOSARCOMA	186
8.2.3.1	INSTRUMENT-BASED	186
8.2.3.1.1	ULTRASOUND SCANNING	187
8.2.3.1.2	IMAGING DEVICES	187
8.2.3.1.3	TESTS	187
8.2.3.1.4	OTHERS	187
8.2.3.2	PROCEDURE-BASED	188
8.2.3.2.1	ENDOMETRIAL BIOPSY	188
8.2.3.2.2	HYSTEROSCOPY	188
8.2.3.2.3	DILATION & CURETTAGE	188
8.2.3.2.4	CYSTOSCOPY	188
8.2.3.2.5	PROCTOSCOPY	188
8.2.3.2.6	OTHERS	189
8.2.4	PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM	189
8.2.4.1	INSTRUMENT-BASED	189
8.2.4.1.1	ULTRASOUND SCANNING	189
8.2.4.1.2	IMAGING DEVICES	190
8.2.4.1.3	TESTS	190
8.2.4.1.4	OTHERS	190
8.2.4.2	PROCEDURE-BASED	190
8.2.4.2.1	ENDOMETRIAL BIOPSY	190
8.2.4.2.2	HYSTEROSCOPY	190
8.2.4.2.3	DILATION & CURETTAGE	191
8.2.4.2.4	CYSTOSCOPY	191
8.2.4.2.5	PROCTOSCOPY	191
8.2.4.2.6	OTHERS	191
8.3	UTERINE SARCOMA	191

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.3.1	LEIOMYOSARCOMA	192
8.3.1.1	INSTRUMENT-BASED	192
8.3.1.1.1	ULTRASOUND SCANNING	193
8.3.1.1.2	IMAGING DEVICES	193
8.3.1.1.3	TESTS	193
8.3.1.1.4	OTHERS	193
8.3.1.2	PROCEDURE-BASED	194
8.3.1.2.1	ENDOMETRIAL BIOPSY	194
8.3.1.2.2	HYSTEROSCOPY	194
8.3.1.2.3	DILATION & CURETTAGE	194
8.3.1.2.4	CYSTOSCOPY	194
8.3.1.2.5	PROCTOSCOPY	194
8.3.1.2.6	OTHERS	195
8.3.2	ENDOMETRIAL STROMAL SARCOMA	195
8.3.2.1	INSTRUMENT-BASED	195
8.3.2.1.1	ULTRASOUND SCANNING	195
8.3.2.1.2	IMAGING DEVICES	196
8.3.2.1.3	TESTS	196
8.3.2.1.4	OTHERS	196
8.3.2.2	PROCEDURE-BASED	196
8.3.2.2.1	ENDOMETRIAL BIOPSY	196
8.3.2.2.2	HYSTEROSCOPY	196
8.3.2.2.3	DILATION & CURETTAGE	197
8.3.2.2.4	CYSTOSCOPY	197
8.3.2.2.5	PROCTOSCOPY	197
8.3.2.2.6	OTHERS	197
8.3.3	UNDIFFERENTIATED SARCOMA	197
8.3.3.1	INSTRUMENT-BASED	198
8.3.3.1.1	ULTRASOUND SCANNING	198
8.3.3.1.2	IMAGING DEVICES	198
8.3.3.1.3	TESTS	198
8.3.3.1.4	OTHERS	198
8.3.3.2	PROCEDURE-BASED	199
8.3.3.2.1	ENDOMETRIAL BIOPSY	199
8.3.3.2.2	HYSTEROSCOPY	199
8.3.3.2.3	DILATION & CURETTAGE	199
8.3.3.2.4	CYSTOSCOPY	199
8.3.3.2.5	PROCTOSCOPY	200
8.3.3.2.6	OTHERS	200
9	NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP	201
9.1	OVERVIEW	202
9.2	>60 YEARS	205
9.3	51-60 YEARS	206
9.4	41-50 YEARS	207
9.5	31-40 YEARS	208
9.6	<30 YEARS	209
10	NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER	210

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.1 OVERVIEW	211
10.2 HOSPITALS	214
10.3 DIAGNOSTIC CENTERS	215
10.4 CANCER RESEARCH CENTERS	216
10.5 AMBULATORY SURGICAL CENTERS	217
10.6 SPECIALIZED CLINICS	218
10.7 OTHERS	219
11 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL	220
11.1 OVERVIEW	221
11.2 DIRECT TENDER	224
11.3 THIRD PARTY DISTRIBUTORS	225
11.4 OTHERS	226
12 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY REGION	227
12.1 NORTH AMERICA	228
12.1.1 U.S.	244
12.1.2 CANADA	255
12.1.3 MEXICO	266
13 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE	279
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA	279
14 SWOT ANALYSIS	280
15 COMPANY PROFILE	281
15.1 KONINKLIJKE PHILIPS N.V.	281
15.1.1 COMPANY SNAPSHOT	281
15.1.2 REVENUE ANALYSIS	281
15.1.3 COMPANY SHARE ANALYSIS	282
15.1.4 PRODUCT PORTFOLIO	282
15.1.5 RECENT DEVELOPMENTS	282
15.2 CANON MEDICAL SYSTEMS ANZ PTY LIMITED.	284
15.2.1 COMPANY SNAPSHOT	284
15.2.2 COMPANY SHARE ANALYSIS	284
15.2.3 PRODUCT PORTFOLIO	285
15.2.4 RECENT DEVELOPMENTS	285
15.3 GENERAL ELECTRIC COMPANY	286
15.3.1 COMPANY SNAPSHOT	286
15.3.2 REVENUE ANALYSIS	286
15.3.3 COMPANY SHARE ANALYSIS	287
15.3.4 PRODUCT PORTFOLIO	287
15.3.5 RECENT DEVELOPMENTS	287
15.4 SIEMENS HEALTHCARE GMBH	289
15.4.1 COMPANY SNAPSHOT	289
15.4.2 REVENUE ANALYSIS	289
15.4.3 COMPANY SHARE ANALYSIS	290
15.4.4 PRODUCT PORTFOLIO	290
15.4.5 RECENT DEVELOPMENTS	290
15.5 FUJIFILM CORPORATION	291
15.5.1 COMPANY SNAPSHOT	291
15.5.2 REVENUE ANALYSIS	291

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.5.3 COMPANY SHARE ANALYSIS	292
15.5.4 PRODUCT PORTFOLIO	292
15.5.5 RECENT DEVELOPMENTS	292
15.6 AED.MD	294
15.6.1 COMPANY SNAPSHOT	294
15.6.2 PRODUCT PORTFOLIO	294
15.6.3 RECENT DEVELOPMENTS	294
15.7 ARQUER DIAGNOSTICS LTD	295
15.7.1 COMPANY SNAPSHOT	295
15.7.2 PRODUCT PORTFOLIO	295
15.7.3 RECENT DEVELOPMENTS	295
15.8 B. BRAUN SE	296
15.8.1 COMPANY SNAPSHOT	296
15.8.2 PRODUCT PORTFOLIO	296
15.8.3 RECENT DEVELOPMENTS	296
15.9 ESAOTE SPA	297
15.9.1 COMPANY SNAPSHOT	297
15.9.2 PRODUCT PORTFOLIO	297
15.9.3 RECENT DEVELOPMENTS	297
15.10 F. HOFFMANN-LA ROCHE LTD	299
15.10.1 COMPANY SNAPSHOT	299
15.10.2 REVENUE ANALYSIS	299
15.10.3 PRODUCT PORTFOLIO	300
15.10.4 RECENT DEVELOPMENTS	300

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

NA Uterine Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 320 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2025-05-04
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com